In briefBMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7111.763b (Published 27 September 1997) Cite this as: BMJ 1997;315:763
Malaria guidelines emphasise risks of preventive treatment: New guidance from the Malaria Reference Laboratory says that the risk of malaria must be balanced against the risk of adverse reactions to antimalarial drugs. Mefloquine treatment carries the risk of neuropsychiatric reactions, so it should be used only when the risk of acquiring malaria that is highly resistant to chloroquine is high (Communicable …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial